Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Indra Nooyi on Leadership, Culture, and Success
04:00pm, Saturday, 10'th Dec 2022 The Motley Fool
Steve Jobs is on Nooyi's list of great leaders, along with lesser-known names.
Stocks To Watch: Eyes On Pfizer, Yum Brands, Oracle And Centene
03:00pm, Saturday, 10'th Dec 2022 Seeking Alpha
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week.
PFIZER VS MODERNA; Which Pharmaceutical Is A Better Stock To Buy Now?
10:30am, Saturday, 10'th Dec 2022
Pfizer VS Moderna Third Quarter Earnings And Revenue
FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids
04:14pm, Friday, 09'th Dec 2022 Zacks Investment Research
Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young
Omicron subvariants are now dominant in the U.S. as COVID cases tick up and New York City becomes a hot spot
03:22pm, Friday, 09'th Dec 2022 MarketWatch
Omicron subvariants continued to account for far more new COVID cases in the U.S. in the latest week than did BA.5, according to the CDC.
Pharma Stock Roundup: SNY, GSK, PFE Relieved on Zantac Win & Other Updates
02:16pm, Friday, 09'th Dec 2022 Zacks Investment Research
A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.
FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids
12:48pm, Friday, 09'th Dec 2022
Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young
Get ready for a 'confusing' respiratory illness season
12:14pm, Friday, 09'th Dec 2022 MarketWatch
There are currently higher-than-normal levels of RSV and the flu in the U.S. At the same time, the number of new COVID-19 infections is rising.
Zacks Market Edge Highlights: LLY, PFE, JPM, ULTA, QQQ
10:41am, Friday, 09'th Dec 2022 Zacks Investment Research
LLY, PFE, JPM, ULTA, QQQ have been highlighted in this Market Edge article.
Is Prometheus Biosciences a Good Stock to Buy Right Now?
10:32am, Friday, 09'th Dec 2022 The Motley Fool
This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead.
Pfizer and BioNTech get FDA fast track designation for single-dose COVID and flu vaccine candidate
06:54am, Friday, 09'th Dec 2022
Pfizer Inc. PFE, +3.07% and German partner BioNTech SE BNTX, +5.64% said Friday they have received fast track designation from the U.S. Food and Drug Administration for a single-dose-mRNA-based vaccin
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
03:01am, Friday, 09'th Dec 2022
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months.
Will There be a Recession in 2023?
07:16pm, Thursday, 08'th Dec 2022 Zacks Investment Research
Tracey Ryniec and John Blank are back with their annual look at the economy and how to invest in the new year.
GSK & Others Get Relief as US Court Dismisses Zantac Litigation
04:02pm, Thursday, 08'th Dec 2022 Zacks Investment Research
A U.S. district court dismisses thousands of lawsuits involving Zantac. Relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE).
Pfizer (PFE) RSV Vaccine Candidate BLA Gets FDA's Priority Tag
03:48pm, Thursday, 08'th Dec 2022 Zacks Investment Research
The FDA's decision on Pfizer's (PFE) BLA seeking approval for RSV vaccine candidate in older adults is expected in May 2023.
